Inovio Pharmaceuticals' Universal H7N9 DNA Vaccine Protects 100% Of Vaccinated Animals In Challenge Study

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has announced that in a preclinical study of its influenza DNA vaccine against the virulent, newly emergent H7N9 flu virus, 100% of the vaccinated animals were protected against sickness and death when they were challenged with a lethal dose of H7N9 virus. The results from a study in mice demonstrated that Inovio's vaccine generated not only hemagglutination inhibition (HAI)-based protection against the H7N9 virus but also strong T-cell responses...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Flu / Cold / SARS Source Type: news